Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia

Abstract This prospective phase II clinical trial evaluated the effects of single-dose mitoxantrone (36 mg/m2 on day 1) in combination with continuous infusion intermediate-dose cytarabine plus etoposide in 25 patients with refractory or early relapsed acute myeloid leukemia (AML). We compared the r...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2009-04, Vol.33 (4), p.511-517
Main Authors: Lee, Sung-Sook, Lee, Je-Hwan, Lee, Jung-Hee, Kim, Dae-Young, Kim, Se Hyung, Lim, Sung-nam, Lee, Young-Shin, Seol, Miee, Ryu, Seong-Gil, Kang, Young-Ah, Jang, Seongsoo, Park, Chan-Jeoung, Chi, Hyun-Sook, Yun, Sung-Cheol, Lee, Kyoo-Hyung
Format: Article
Language:English
Subjects:
Adult
AML
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cytarabine - administration & dosage
Cytarabine - adverse effects
Early relapse
Etoposide - administration & dosage
Etoposide - adverse effects
Female
Hematology, Oncology and Palliative Medicine
Humans
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - mortality
Male
Middle Aged
Mitoxantrone
Mitoxantrone - administration & dosage
Mitoxantrone - adverse effects
Neoplasm Recurrence, Local - drug therapy
Refractory
Salvage Therapy - methods
Single-dose
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract This prospective phase II clinical trial evaluated the effects of single-dose mitoxantrone (36 mg/m2 on day 1) in combination with continuous infusion intermediate-dose cytarabine plus etoposide in 25 patients with refractory or early relapsed acute myeloid leukemia (AML). We compared the results of our current study with those of a previous phase II trial, which had the same eligibility criteria and chemotherapy schedule except that a conventional divided dose of mitoxantrone (12 mg/m2 on days 1–3) was used. The complete remission (CR) rate was significantly lower with the single-dose mitoxantrone regimen than with the divided-dose regimen (24.0% vs. 51.5%; P = 0.034), mainly owing to an increased incidence of hypoplastic deaths. CR duration and overall survival were not significantly different between the two regimens. In conclusion, single-dose mitoxantrone was inferior to conventional divided-dose mitoxantrone for treatment of refractory or early relapsed AML in terms of CR rate.
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2008.08.009